Investigating the Forecasts by Wall Street Analysts on AbbVie's Stock Market Trajectory
Welcome, folks! Let's dive into the world of biopharmaceuticals and check out AbbVie Inc. (ABBV), nestled in North Chicago, Illinois. This company is renowned for its pharmaceutical wonders, operating across immunology, oncology, aesthetics, neuroscience, and eye care arenas. With a whopping market cap of $346.8 billion, AbbVie is more than just a name in the healthcare sector.
The past year has been a golden run for this drug titan. ABBV has galloped ahead by 15%, while the broader S&P 500 Index ($SPX) has merely cantered 8.2%. In the year 2025, it's AbbVie that's galloping into the lead, with a 5.3% rise, outpacing the SPX's 4.7% decline on a year-to-date (YTD) basis.
Wall Street adores a good scuffle, especially patent squabbles. So, marvel at the company standing firm in the retail AI patent arena. Dig deeper with our Active Investor newsletter.
AbbVie's triumphant sprint is crystal clear when compared to the Invesco Pharmaceuticals ETF (PJP). Over the past year, the ETF has merely inched forward. In a YTD tussle, ABBV's returns outshine the ETF's 4.4% dip.
AbbVie has navigated the revenue loss from the blockbuster drug Humira like a pro, launching successful replacements Skyrizi and Rinvoq. Add strategic acquisitions, a robust pipeline, and newer products like Elahere and Epkinly to the mix, and you've got a formula for top-line growth and EPS guidance.
On Apr. 25, the scores rose as ABBV shares soared more than 3% following the release of its Q1 results. The adjusted EPS clocked in at $2.46, beating Wall Street expectations of $2.39. The company's revenue amounted to $13.3 billion, trouncing analyst forecasts of $12.9 billion. AbbVie predicts full-year adjusted EPS in the range of $12.09 to $12.29.
Looking at fiscal year 2025, ending December, analysts expect AbbVie's EPS to soar an impressive 21.4% to $12.29. The company's outstanding earnings beat record spans four consecutive quarters.
Currently, 26 analysts weigh in on ABBV stock, and the consensus is a "Moderate Buy." This is based on 15 "Strong Buys," 2 "Moderate Buys," and 9 "Holds."
If you're still hungry for more, Guggenheim analyst Vamil Divan upped the ante on Apr. 29 by keeping a "Buy" rating on ABBV and ramping up the price target to $216, aimed at a potential climb of 15.4% from current levels.
The average price target of $210.04 signifies a 12.2% premium to ABBV's current prices. The Street's loftiest price target of $250 suggests an jaw-dropping upside potential of 33.6%.
So, stay tuned, as AbbVie Inc. continues to shake up the market and redefine what it means to be a pharma juggernaut!
Disclaimer: On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view our website's Disclosure Policy here.
- AbbVie Inc. (ABBV), a pharmaceutical giant with a market cap of $346.8 billion, has outperformed the market, increasing by 15% in the past year while the S&P 500 Index (SPX) saw an 8.2% increase.
- In 2025, AbbVie is projected to continue this growth, with a 5.3% rise, whereas the SPX is predicted to decrease by 4.7% on a year-to-date basis.
- Currently, 26 analysts recommend a "Moderate Buy" for ABBV stock, with a consensus based on 15 "Strong Buys," 2 "Moderate Buys," and 9 "Holds."
- One analyst, Vamil Divan from Guggenheim, has recently raised the price target for ABBV to $216, suggesting a potential 15.4% increase from current levels, and the street's loftiest price target of $250 indicates a significant upside potential of 33.6%.
